Kaituojia Pharmaceuticals: Subsidiary Reaches Strategic Cooperation with Shangmei Group on KT-939

LightningPacketLoss · 2026-03-18T05:46:37+00:00

Kaituojia Pharmaceutical and Shanghai Shang Mei Cosmetics have signed a strategic cooperation agreement aimed at rapidly commercializing the skin-brightening and spot-removing cosmetic ingredient KT-939, and jointly advancing its registration and research and development in China to achieve mutual market value creation.

LightningPacketLoss

2026-03-18 05:46:37

Abstract generation in progress

Recently, Kintor Pharmaceutical announced that its wholly-owned subsidiary, Suzhou Kintor, has signed a strategic cooperation framework agreement with Shanghai Shangmei Cosmetics Co., Ltd. in the cosmetics field, including exclusive terms. The agreement involves the rapid commercialization of the company’s whitening and spot-removal cosmetic raw material KT-939.

According to the framework agreement, Suzhou Kintor and Shangmei will jointly promote the registration of KT-939 in China and related cosmetic products, as well as conduct research and development and customization of efficacy raw materials, aiming to position KT-939 as a domestically produced whitening agent with industry influence.

The company plans to use the cash flow generated by KT-939 to support the development and commercialization of core products such as KX-826 and GT20029. At the same time, the signing of the framework agreement is based on the high complementarity and strategic synergy between both parties in the fields of cosmetics and biomedicine, aiming to jointly explore markets and achieve value co-creation.

(Kintor Pharmaceutical Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes